Difference between revisions of "Catenacci DV, et al. J. Clin. Oncol. (2015) cited as Ref 607 in DOI: 10.1038/s41392-020-0110-5 (Q9870)"
Jump to navigation
Jump to search
(Created a new Item: #quickstatements; #temporary_batch_1589975872009) |
(Created claim: Page(s) (P105): 4284-4292, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (8 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / First Author string | |||||||||||||||
| + | Catenacci DV | ||||||||||||||
| Property / First Author string: Catenacci DV / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / DOI Identifier | |||||||||||||||
| + | |||||||||||||||
| Property / DOI Identifier: 10.1200/JCO.2015.62.8719 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / PubMed ID | |||||||||||||||
| + | |||||||||||||||
| Property / PubMed ID: 26527777 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2015
| ||||||||||||||
| Property / Publication Date: 2015 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | J. Clin. Oncol. | ||||||||||||||
| Property / Published In Name String: J. Clin. Oncol. / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 33 | ||||||||||||||
| Property / Volume: 33 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib a hedgehog pathway inhibitor in patients with metastatic pancreatic cancer (English) | ||||||||||||||
| Property / title: Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib a hedgehog pathway inhibitor in patients with metastatic pancreatic cancer (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 4284-4292 | ||||||||||||||
| Property / Page(s): 4284-4292 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| links / sliswiki / name | links / sliswiki / name | ||||||||||||||
| + | |||||||||||||||
Latest revision as of 15:46, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Catenacci DV, et al. J. Clin. Oncol. (2015) cited as Ref 607 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Catenacci DV
0 references
2015
0 references
J. Clin. Oncol.
0 references
33
0 references
Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib a hedgehog pathway inhibitor in patients with metastatic pancreatic cancer (English)
0 references
4284-4292
0 references
